Results 191 to 200 of about 113,185 (266)

Correction to: Surgical management of giant splenomegaly in chronic myeloid leukemia: a challenging splenectomy case. [PDF]

J Surg Case Rep
europepmc   +1 more source

Mesenchymal stem cells inhibited chronic myeloid leukemia cells in vitro, correlating with oxidative stress. [PDF]

World J Surg Oncol
Zheng Y, Shi C, Chen Y, Lai B, Wu H, Sheng L, Ge Q, Ouyang G, Yan X.   +8 more
europepmc   +1 more source

Survival outcomes and treatment patterns in myelofibrosis in the JAK inhibitor era

British Journal of Haematology, EarlyView.
Summary Data on real‐world survival and treatment patterns in large, unselected myelofibrosis (MF) cohorts remain limited. We analysed 1649 patients with MF diagnosed from 2010 onwards and included in the Spanish Myelofibrosis Registry across 64 centres. Janus kinase (JAK) inhibitors were administered to approximately half of the patients.
Juan‐Carlos Hernández‐Boluda, Eduardo Arellano‐Rodrigo, Manuel Pérez‐Encinas, José‐María Raya, María‐Teresa Gómez‐Casares, Francisca Ferrer‐Marín, Alberto Hernández‐Sánchez, María‐Laura Fox, Anna Angona, Beatriz Cuevas, María‐Isabel Mata‐Vázquez, Rosa Ayala, Natalia de las Heras, Elvira Mora, Valentín García‐Gutiérrez, Alicia Senín, Jasson Villarreal, Blanca Xicoy, Raúl Pérez‐López, María García‐Fortes, Sonia González de Villambrosia, Elena Magro, María‐José Ramírez, Paula Gómez, Angel Ramírez‐Payer, Clara Martínez‐Valverde, Lucía Pérez‐Lamas, Carmen García‐Hernández, Mercedes Gasior, Luis‐Miguel Juárez‐Salcedo, Francisco Ibáñez, María‐Luisa Antelo, Lucía Guerrero, Alberto Alvarez‐Larrán, Arturo Pereira, on behalf of the Spanish MPN Group (GEMFIN)   +35 more
wiley   +1 more source

Chronic myeloid leukemia presenting with isolated central nervous system lymphoid blast crisis: A case report. [PDF]

Rare Tumors
Zarama-Valenzuela Á, Arévalo-Zambrano M, Cadena-Andrade Á, Zárate-Mesa A.   +3 more
europepmc   +1 more source

Behcet's disease in a patient with chronic myeloid leukemia. [PDF]

Indian J Sex Transm Dis AIDS
Singh D, Somasundaram A, Gajula AS, Kumar S.   +3 more
europepmc   +1 more source

Therapeutic potential of natural products in cancer immunotherapy: Advances and challenges

British Journal of Pharmacology, EarlyView.
This review systematically outlines the mechanisms underlying tumour immunotherapy resistance and elucidates the role of natural products in enhancing therapeutic efficacy as immunomodulatory adjuvants. Abstract Immunotherapy has emerged as a clinically pivotal approach in cancer treatment, but its application remains limited to a small subset of ...
Rao Hu, Kaibin Dai, Zhensheng Lin, Mingfang Ye, Minfeng Chen, Xiaobo Li, Dongmei Zhang   +6 more
wiley   +1 more source

Targeting protein–protein interactions with reversible covalent modalities: Non‐cysteine chemistries

British Journal of Pharmacology, EarlyView.
Abstract Protein–protein interactions (PPIs) are central to diverse cellular functions, and represent a rapidly expanding class of therapeutic targets. Advancements in covalent drug design have enabled small‐molecule drugs to overcome challenges associated with engaging these targets, such as limited durations of action and difficult‐to‐drug (expansive,
Ruchira Basu, Steven Fletcher
wiley   +1 more source

Chronic Myeloid Leukemia After Liver Transplantation and the Role of Immunosuppression: A Case Report. [PDF]

Cureus
Gupta N, Solanki S, Deshmukh A, Avalareddy A, Sakpal M, Ganjoo N, Hukkeri V, Sandhyav R, Girn HRS, Asthana S.   +9 more
europepmc   +1 more source

Early venetoclax dose escalation at minimal residual disease progression may benefit selected acute myeloid leukaemia patients

British Journal of Haematology, EarlyView.
Sari Kytölä, Anu Partanen, Milla E. L. Kuusisto, Sirpa Koskela, Annasofia Holopainen, Ida Vänttinen, Tanja Ruokoranta, Pia Ettala, Johanna Rimpiläinen, Timo Siitonen, Marja Pyörälä, Heikki Kuusanmäki, Mika Kontro   +12 more
wiley   +1 more source

Targeting KRAS for cancer therapy

British Journal of Pharmacology, EarlyView.
In recent years, therapeutics targeted against KRAS proto‐oncogene GTPase (KRAS)‐mutant cancers have seen significant progress. Herein we outline the biology and epidemiology of KRAS alterations at the lineage and allele levels, reviewing the clinical evidence for KRASG12C inhibition from the discovery of the recessive switch pocket to sotorasib ...
Jianlong Jia, Ruonan Liu, Tonia A. Adamide, Isis E. Fernandez, Georgios T. Stathopoulos   +4 more
wiley   +1 more source